Transmitter-mediated local contracture of the endplate region of the focally innervated mouse diaphragm treated with anticholinesterase.
1. Local contraction of the endplate region in response to nerve stimulation was studied in isolated mouse diaphragms. In normal preparations, muscle contractions involved the whole length of the muscle fibre with rise and decay times in the order of tens of ms whether evoked with a single or train of pulses. 2. When acetylcholinesterase was inhibited with neostigmine, tetanic stimulation produced a twitch-like phasic contraction and a delayed tonic contracture. A brief train of pulse (10 ms, 300 Hz) was enough to trigger a full size tonic contracture which reached an amplitude about one tenth that of control tetanus and had a duration of about 4 s. 3. Tetanic stimulation evoked a non-propagating prolonged depolarization at the endplate region lasting for about 1 s following a few muscle action potentials. 4. mu-Conotoxin, a specific inhibitor of muscle Na+ channel, selectively abolished the phasic contraction and the muscle action potentials leaving the tonic contracture and the prolonged depolarization unaffected. 5. Both the tonic contracture and the prolonged depolarization were highly sensitive to blockade by tubocurarine (IC50 0.05-0.1 microM) and vesamicol (1 microM, an inhibitor of packaging acetylcholine into synaptic vesicles), were attenuated by increasing Ca2+ concentration and were prolonged by decreasing Ca2+. 6. The results suggest that prolonged activation of endplate nicotinic receptors by endogenously released transmitter can produce substantial contractions of the endplate region when acetylcholinesterase are inhibited. The source of Ca2+ for the contraction seems to come mainly from intracellular stores.
Hong
S J
SJ
Department of Pharmacology, College of Medicine, National Taiwan University, Taipei.
Chang
C C
CC
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D003964:Diaphragm / Q000187:drug effects / Q000294:innervation / Q000502:physiology; D004558:Electric Stimulation; D005559:Formamides / Q000494:pharmacology; D066298:In Vitro Techniques; D051379:Mice; D008813:Mice, Inbred ICR; D009045:Motor Endplate / Q000187:drug effects / Q000502:physiology*; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009388:Neostigmine / Q000494:pharmacology; D009467:Neuromuscular Depolarizing Agents / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000502:physiology*; D010455:Peptides / Q000494:pharmacology; D010791:Phrenic Nerve / Q000187:drug effects / Q000502:physiology; D010880:Piperidines / Q000494:pharmacology; D012132:Respiratory Muscles / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D014403:Tubocurarine / Q000494:pharmacology; D020960:omega-Conotoxins
D002800:Cholinesterase Inhibitors; D005559:Formamides; D009467:Neuromuscular Depolarizing Agents; D018377:Neurotransmitter Agents; D010455:Peptides; D010880:Piperidines; D020960:omega-Conotoxins; C053423:Conus magus toxin; D009388:Neostigmine; C006189:vesamicol; D002118:Calcium; D014403:Tubocurarine